Fundamental Analysis of NABRIVA THERAPEUTICS PLC(NASDAQ:NBRV) stock

Fundamental Rating

Overall NBRV gets a fundamental rating of 1 out of 10. We evaluated NBRV against 198 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of NBRV have multiple concerns. NBRV is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year NBRV has reported negative net income.

NBRV had a negative operating cash flow in the past year.

In the past 5 years NBRV always reported negative net income.

In the past 5 years NBRV always reported negative operating cash flow.

1.2 Ratios

The profitability ratios for NBRV are negative, so there is not much use analyzing them.

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 18.76%, NBRV is in line with its industry, outperforming 50.24% of the companies in the same industry.

In the last couple of years the Gross Margin of NBRV has declined.

The Profit Margin and Operating Margin are not available for NBRV so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	18.76%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-38.92%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

NBRV does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for NBRV has been increased compared to 1 year ago.

NBRV has less shares outstanding than it did 5 years ago.

The debt/assets ratio for NBRV is higher compared to a year ago.

2.2 Solvency

NBRV has an Altman-Z score of -5.39. This is a bad value and indicates that NBRV is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -5.39, NBRV is doing worse than 66.82% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-5.39

ROIC/WACCN/A

WACC6.62%

2.3 Liquidity

A Current Ratio of 0.85 indicates that NBRV may have some problems paying its short term obligations.

The Current ratio of NBRV (0.85) is worse than 90.52% of its industry peers.

NBRV has a Quick Ratio of 0.85. This is a bad value and indicates that NBRV is not financially healthy enough and could expect problems in meeting its short term obligations.

With a Quick ratio value of 0.52, NBRV is not doing good in the industry: 93.84% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	0.85
Quick Ratio	0.52

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 20.40% over the past year.

Looking at the last year, NBRV shows a small growth in Revenue. The Revenue has grown by 6.16% in the last year.

NBRV shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 47.33% yearly.

EPS 1Y (TTM)20.4%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q45.93%

Revenue 1Y (TTM)6.16%

Revenue growth 3Y57.35%

Revenue growth 5Y47.33%

Revenue growth Q2Q-5.36%

3.2 Future

Based on estimates for the next years, NBRV will show a very strong growth in Earnings Per Share. The EPS will grow by 21.90% on average per year.

Based on estimates for the next years, NBRV will show a very strong growth in Revenue. The Revenue will grow by 38.14% on average per year.

EPS Next Y49.57%

EPS Next 2Y39.49%

EPS Next 3Y30.2%

EPS Next 5Y21.9%

Revenue Next Year89.23%

Revenue Next 2Y66.62%

Revenue Next 3Y52.98%

Revenue Next 5Y38.14%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NBRV. In the last year negative earnings were reported.

Also next year NBRV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as NBRV's earnings are expected to grow with 30.20% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y39.49%

EPS Next 3Y30.2%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

NBRV does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

NABRIVA THERAPEUTICS PLC

NASDAQ:NBRV (7/31/2023, 7:00:01 PM)

After market: 1.3986 -0.02 (-1.51%)

1.42

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap4.55M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	18.76%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover1.5

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	0.85
Quick Ratio	0.52
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)20.4%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y49.57%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)6.16%

Revenue growth 3Y57.35%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

NABRIVA THERAPEUTICS PLC (NBRV)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens